Increased expression of PELP1 in human sperm is correlated with decreased semen quality

Izabela Skibinska¹, Miroslaw Andrusiewicz¹, Michal Soin¹, Magdalena Jendraszak¹, Paulina Urbaniak¹, Piotr Jedrzejczak², Małgorzata Kotwicka¹

Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) is a scaffolding protein involved in both genomic and nongenomic estrogen signal transduction pathways. To date, the role of PELP1 protein has yet to be characterized in human sperm and has not been associated with sperm parameters. To confirm the presence of PELP1 in human sperm, fresh semen samples were obtained from 178 donors. The study was designed to establish both mRNA and protein presence, and protein cellular localization. Additionally, the number of PELP1-positive spermatozoa was analyzed in men with normal and abnormal semen parameters. Sperm parameters were assessed according to the World Health Organization (WHO) 2010 standards. The presence of PELP1 in spermatozoa was investigated using four precise, independent techniques. The qualitative presence of transcripts and protein was assessed using reverse transcription-polymerase chain reaction (RT-PCR) and western blot protocols, respectively. The cellular localization of PELP1 was investigated by immunocytochemistry. Quantitative analysis of PELP1-positive cells was done by flow cytometry. PELP1 mRNA and protein was confirmed in spermatozoa. Immunocytochemical analysis identified the presence of PELP1 in the midpieces of human sperm irrespective of sperm parameters. Becton Dickinson fluorescence-activated cell sorting (FACS Calibur™) analysis revealed a significantly lower number of PELP1-positive cells in males with normal semen parameters versus abnormal samples (42.78% ± 11.77% vs 61.05% ± 21.70%, respectively; P = 0.014). The assessment of PELP1 may be a time-saving method used to obtain information about sperm quality. The results of our study suggest that PEPL1 may be utilized as an indicator of sperm quality; thereby, PELP1 may be an additional biomarker useful in the evaluation of male infertility.

Asian Journal of Andrology (2018) 20, 425–431; doi: 10.4103/aja.aja_11_18; published online: 20 April 2018

Keywords: male infertility; proline-, glutamic acid-, and leucine-rich protein 1; semen parameters; sperm quality; spermatozoa

INTRODUCTION

Infertility affects over 50 million couples, and potentially as many as 186 million people worldwide suffer from fertility issues. Due to limitations regarding precise numbers, the male factor is expected to contribute toward approximately half of all infertility cases. The current diagnostic approaches focus on analysis of standard semen parameters: motility, morphology, and sperm count. Regardless, up to one-third of infertile males are considered as possessing idiopathic sperm abnormalities. However, this issue becomes difficult to address as some sperm donors who do not show abnormalities in semen parameters display issues with conception. It is suggested that, in some cases, molecular defects leading to conception failure may be the root of the problem. Increasing evidence indicates that basic semen analysis does not fully encompass the potential of male fertility.

For this reason, plausible sperm biomarkers, such as the expression patterns of sperm RNAs and protein, need to be evaluated instead of reliance on the standard semen parameters. These factors could play a functional role after delivery to the oocyte, or they may play a part in modulation of gene expression processes. The amount of particular RNAs and/or proteins may be a distinguishing factor between fertile and infertile men, even when the latter present normal semen parameters. In this manner, molecular biomarkers are thought to be a promising area of specific and suitable therapeutic tools in fertility issues’ exploration.

Sperm viability parameters are essential for successful conception, and they depend on complex orchestration of biological systems. It is postulated that steroid hormones play a crucial role in the spermatogenesis process. Recently, attention was focused on estrogens, androgens, and their cognate receptors. Steroid hormones can affect target cells via genomic and/or nongenomic mechanisms, creating a network of proteins involved in signal transduction. Estrogen plays a critical role in the male reproductive system as it is essential for its proper development as well as the process of spermatogenesis. It has been suggested that the target cells for estrogen can also be human sperm cells. Recent studies demonstrated that estrogens modulate sperm motility, capacitation, and acrosome reaction. Estrogens affect target cells via specific estrogen receptors (ESRs): ESR1 and ESR2. Spermatozoa possess both forms of the ESRs as well as aromatase, the enzyme that converts testosterone to estrogen, indicating that these proteins are key factors in the male reproductive system. Our previous studies showed the presence of ESRs in the midpiece

¹Department of Cell Biology, Faculty of Health Sciences, Poznan University of Medical Sciences, Rakietnicka 5D, Poznan 60-806, Poland; ²Division of Infertility and Reproductive Endocrinology, Faculty of Medicine I, Poznan University of Medical Sciences, Polna 33, Poznan 60-535, Poland.

Correspondence: Dr. I Skibinska (iskibinska@ump.edu.pl)

Received: 12 August 2017; Accepted: 20 December 2017
region of sperm, suggesting their importance in the context of mitochondrial function.21,23

Novel findings indicate the primary role of proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) in crosstalk between cellular processes mediated via ESR. Additionally, the mechanistic relationship between G protein-coupled estrogen receptor (GPER30) and the estrogen-related signaling pathway has been reported.24 Because many environmental factors are described as endocrine estrogen disruptors, which may bind to ESR, GPER30, and the androgen receptor,25 it is essential to trace the molecular pathway of estrogen action in males. As a result, PELP1 would be placed among the molecules involved in signal modulation of rapid estrogen signaling, particularly in sperm cells.

PELP1 is present both within the cell nucleus and cytoplasm. The genomic action of PELP1 may influence gene expression by binding to H3 and H4 histones and, as a consequence, remodels chromatin structure. Nongenomically, PELP1 is engaged in estrogen-dependent signal transduction based on a social network of phosphorylated protein complexes.26–28 It also participates in ribosome biogenesis and serves as a protein–protein mediator in various cellular processes.26,30 PELP1 RNA levels and protein expression in mature sperm cells are under scrutiny.31

Taking into consideration the influence of environmental estrogen-like compounds on the biology of male reproductive system and sperm cells, the aim of our study was to determine a PELP1 expression pattern and compare it with sperm parameters. As postulated, this protein is essential for estradiol-mediated, extranuclear response, and thus plays a crucial role in signal transduction in spermatozoa. We analyzed PELP1 mRNA and protein concentrations in pooled semen samples. First of all, we confirmed its presence in sperm, and then we estimated its cellular localization in the spermatozoa and determined the proportion of PELP1 in subjects presenting normal and abnormal semen parameters.

MATERIALS AND METHODS

Ethical approval statement

The Institutional Review Board at the Poznan University of Medical Sciences, Poznan, Poland, approved this study (No. 553/13). Written informed consent was obtained from each participant.

Materials

Semen samples were obtained from 178 men at the Division of Infertility and Reproductive Endocrinology of Poznan University of Medical Sciences. All participants were of Caucasian descent. All patients have been undergoing the diagnostic procedures due to infertility of unknown cause. Varicocele, prostate dysfunction, vas deferens obstruction, as well as metabolic diseases were excluded.

Semen samples of 43 men, aged 18–45 years (median age 33 years), were evaluated according to the World Health Organization (WHO) guidelines for normozoospermia: concentration above \(15 \times 10^6\) sperm ml\(^{-1}\), at least 58% live sperm, >32% sperm showing progressive movement, more than 4% spermatozoa with normal morphology, and a leukocyte content of <10 cells ml\(^{-1}\).32 Seventeen samples were classified as normozoospermic according to the WHO standards and 26 samples which did not meet any of above-mentioned criteria, thereby, were qualified as abnormal (Supplementary Table 1).

All 43 semen samples used for Becton Dickinson fluorescence-activated cell sorting (FACSCalibur\textsuperscript{TM}; Becton-Dickinson, Franklin Lakes, NJ, USA) analyses were obtained from each patient. Only one sample from each patient was used for the analysis. Sperm smears were prepared using 10 µl of the whole semen volume, and the remaining part was examined by FACSCalibur\textsuperscript{TM} flow cytometry (Becton-Dickinson). Further investigations were performed at the Cell Biology Department of Poznan University of Medical Sciences. A schematic diagram describing semen sample acquisition is shown in Figure 1.

mRNA and protein presence validation

Due to the small amount of RNA in spermatozoa, nine separate trials of pooled semen samples were obtained from 12–18 donors (\(n = 135\)). Half of the pooled sample volume was used for RNA extraction and the other half for protein isolation. Swim-up technique was used to obtain a pure fraction of sperm cells from each sample according to the WHO guidelines.32

Analysis of PELP1 mRNA expression

Total RNA was isolated using TriPure isolation reagent (Roche, Basel, Switzerland) according to a modified Chomczynski and Sacchi method.33 The modifications included repeated TriPure isolation step and RNA precipitation at −80°C instead of room temperature (RT) incubation, followed by nucleic acid concentration using a silica matrix column system (ZymoResearch, Irvine, CA, USA). Additionally, the repeated TriPure step during RNA extraction prevented DNA contamination. RNA sample quantity and purity was assessed by measuring absorbance (NanoDrop ND-1000 spectrophotometer; Thermo Fisher Scientific, Waltham, MA, USA) at A260 nm, A230 nm, and A280 nm; and the A230/260 and A260/280 ratios showed that all samples met the criteria for purity (both ratios ranged from 1.9 to 2.0). To evaluate sample integrity, the ribosomal RNA bands were analyzed by 0.8% agarose gel electrophoresis in denaturing conditions of 1 µg RNA in 1 × FA buffer (pH 7.0, 1 mmol l\(^{-1}\) ethylenediaminetetraacetic acid, 5 mmol l\(^{-1}\) sodium acetate, 20 mmol l\(^{-1}\) 3-(N-morpholino)-propanesulfonic acid [free acid; Sigma-Aldrich, Saint Louis, MO, USA]) and 0.8% paraformaldehyde (Avantor Performance Materials Poland S.A.,

Figure 1: Schematic diagram of the sperm analysis procedure. Analysis of pooled semen samples (top) and individually analyzed donations (bottom). RT-qPCR: reverse transcription-quantitative polymerase chain reaction.
Gliwice, Poland) providing denaturing conditions in the presence of ethidium bromide (Sigma-Aldrich).

The reverse transcription reaction was performed according to the Transcriptor reverse transcriptase manufacturer protocol (Roche). The total reaction volume was 10 µl. In the first step, 500 ng of total cellular RNA, DNase, RNase, pyrogen-free water, and 5 pmol universal oligo (dT)12 primer were combined, and the samples were denatured at 65°C for 10 min then cooled on ice. Next, each sample was complemented with 5 pmol µl−1 of each deoxyribonucleotide triphosphates (dNTPs), 10U for reaction (rnx) ribonuclease inhibitor, 1 × buffer (Transcriptor RT buffer; Roche, Basel, Switzerland), and 10U for rnx of reverse transcriptase. The following thermal profile was applied: 25°C for 10 min, 55°C for 60 min, then 5 min at 85°C.

cDNA was immediately used for quantitative polymerase chain reaction (qPCR) or stored at −20°C until further analysis (but no longer than 1 week).

To establish RNA expression, the LightCycler® 2.0 carousel glass capillary-based system was applied (Roche). Primer sequences and TaqMan® hydrolysis probe were chosen for the gene of interest (GOI) were determined using Roche Universal Probe Library Assay Design Center (https://lifescience.roche.com/en_pl/brands/universal-probe-library.html, last accessed on September 28, 2017). The hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene encoding hypoxanthine-guanine phosphoribosyltransferase was served as an internal control (Roche assay N° 05046157001). The reaction mixture in a total volume of 20 µl contained 5 µl template cDNA (obtained in the reverse transcription reaction step), 1 × LightCycler® FastStart TaqMan® Probe Master (Roche), 0.1 µmol l−1 hydrolysis probe (0.2 µmol l−1 in the case of GOI), and 0.5 µmol l−1 gene-specific primers. The Universal Probe Library (UPL) probe and the sense and antisense primers for the GOI were as follows: probe #62 (Roche cat. N°: 04688619001) and 5'-GCACTGTGTGCTTTGCGA-3’ and 5'-GAGGAGGTCCTCAGGACA-3’. The primers were designed so that they annealed in two different exons spaced by a 7.9-kb intron.

We used the standard cycling and acquisition reaction profile for UPL probes. Each reaction was performed in duplicate on independently synthetized cDNA. Samples were sequenced to confirm their identity with those deposited in the Nucleotide Database of National Center for Biotechnology Information (GenBank N°: NM_014389.2).

**PELP1 protein detection**

Sperm cells were suspended in an appropriate volume of isolation buffer (80% phosphate-buffered saline [PBS; PAN-biotech, Aidenbach, Germany]) 10% protein extraction and immunoprecipitation 1 × radio-immunoprecipitation assay (RIPA) buffer (Merck Millipore, Darmstadt, Germany); and 10% protease inhibitor cocktail (Sigma-Aldrich). The samples were incubated for 15 min at 4°C with gentle shaking, then cells were centrifuged (Centrifuge 5812R; Eppendorf, Hamburg, Germany) at 12 000 g, 4°C, 15 min., and the supernatants containing protein extracts were used for western blot analysis. Quick Start Bradford Dye Reagent (BioRad, Hercules, CA, USA) and spectrophotometer (NanoDrop ND-1000; Thermo Fisher Scientific) were used for colorimetric measurement of extracted proteins (595 nm wavelength) and referred to decimal dilution series of bovine serum albumin fraction V (BSA V; Roche).

Thirty micromicrograms of extracted proteins were separated using 12% SDS-PAGE running buffer (25 mmol l−1 Tris, 192 mmol l−1 glycine, 0.1% SDS, pH 8.3 [LabEmpire, Rzeszow, Poland]; 200V, 40 min, RT) and subsequently transferred to activated Hybond-P polyvinylidene fluoride membrane (GE Healthcare Europe, Little Chalfont, UK) in transfer buffer (1 × SDS-PAGE running buffer supplemented with 20% methanol; 300 mA, 90 min, RT). After blotting, membranes were incubated for 1 h at 4°C in Tris-buffered saline with Tween 20 (TBST) buffer (5% BLOTTO blocking reagent solution [BioRad]; 1 × TBST). Protein detection was evaluated using primary polyclonal anti-PELP1 rabbit antibody (Bethyl Laboratories, Montgomery, TX, USA) followed by incubation with polyclonal anti-rabbit alkaline phosphatase-conjugated goat secondary antibody (Sigma-Aldrich), both at a 1:2500 dilution (200 rpm orbital shaker, 1 h, 4°C). Each time, unbounded antibodies were rinsed three times in TBST buffer (200 rpm, 10 min, RT). Glyceraldehyde 3-phosphate dehydrogenase protein (GAPDH) extracted from spermatozoa, as well as from the ovarian cancer cell line OVCAR-3 (ATCC, Manassas, VA, USA), was used as internal and external positive control for PELP1 expression. Visualization was performed using the BCIP®/NBT-Blue liquid substrate system for membranes (Sigma-Aldrich). Membranes were digitized using G:BOX Chemi system (Syngene, Cambridge, UK). Western blots were repeated in triplicate for all 9 pooled samples.

**Immunocytochemistry**

Smears were fixed on glass microscope slides in a 4% buffered paraformaldehyde solution (Avantor Performance Materials Poland S.A.) for 10 min at RT. In order to retrieve antigens, the slides were boiled in a microwave oven twice (2 × 10 min, 200W) in citrate buffer (pH 6.0, 0.1 mol l−1 citric acid solution, 0.1 mol l−1 sodium citrate solution; Avantor Performance Materials Poland S.A.) and then cooled at RT. In order to block endogenous peroxidase activity, slides were incubated for 3 min in 3% hydrogen peroxide solution (Avantor Performance Materials Poland S.A.). To avoid nonspecific antibody binding, the slides were placed in TBST buffer (containing 3% BSA) for 1 h at RT. To evaluate PELP1 protein localization, the same primary antibodies (Bethyl Laboratories) as for western blot were used at a 1:500 dilution. Incubation was carried out overnight at 4°C. Subsequently, the slides were rinsed three times for 15 min in TBST buffer. In order to identify cellular localization of the antigen, the slides were processed with commercial Dako EnVision® System HRP (DAB) kit (Dako, Glostrup, Denmark) containing a horseradish peroxidase-conjugated anti-rabbit secondary antibody. The detection procedure was provided by the manufacturer. As positive controls, 3 µm dewaxed and rehydrated tissue specimen sections of ovarian cancer were used. Evaluation was performed under the Axioshot light microscope (Zeiss-Opton, Oberkochen, Germany).

**Flow cytometry**

Cells were separated using a gradient isolation system (Sil-Select Plus, FertiPro N.V., Beernem, Belgium) according to the manufacturer’s protocol. Sperm cells from the lower phase were harvested and pelleted (300 g, 10 min, RT), and spermatozoa were fixed in an appropriate volume of 4% buffered paraformaldehyde solution (1 h, RT) followed by centrifugation 10 min, 200 g, 4°C (Centrifuge 5415D, Eppendorf). Next, cells were permeabilized on ice for 20 min in 500 µl 0.1% saponin solution in PBS supplemented with 0.5% BSA. Samples were then centrifuged again under the same conditions, and 100 µl of PELP1 primary polyclonal antibodies were applied at a 1:500 dilution. The incubation period was 1 h on ice. Next, the solution was filled up with saponin (to the maximum volume of the 1.5 ml eppendorf tube), centrifuged (200 g, 5 min, 4°C), and washed with PBS. The next step was a 30-min incubation on ice in darkness with secondary goat anti-rabbit antibody conjugated with fluorescein (Santa Cruz Biotechnology Inc., Dallas, TX, USA) at a 1:100 dilution.
Samples were then filled with saponin solution, centrifuged, and suspended in 500 µl PBS. In the negative control, samples omitted the primary antibody. For each experiment performed using BD FACSCalibur™ flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA), 10,000 cells were examined. The fluorescence dye was excited by argon laser (488 nm) and emission was measured in the FL1 channel (515–545 nm). All data were gathered and analyzed using BD CellQuest™ Pro software (version 5.2; Becton Dickinson). The FACS operator was blinded for the results of the semen analyses. The intensity of fluorescence of PELP1-positive cells derived from patients presenting abnormal semen parameters was compared to the values obtained from patients fulfilling the criteria for normozoospermia.

Statistical analysis
Statistical analysis was performed using Statistica version 12 software for Windows (StatSoft Inc., Tulsa, OK, USA). To describe experimental results, mean ± standard deviation was used. The Shapiro–Wilk test was used for the normality of continuous variables distribution assessment. The Welch’s t-test, as well as Mann–Whitney U-test, was applied. The correlation coefficient (r) between sperm parameters and mean fluorescent intensity was determined by the Spearman’s rank correlation tests. Using the Medical plugin version 4.0 for Statistica software (StatSoft), the receiver operating characteristic (ROC) curve was created. Subsequently, Hanley and McNeil methods for ROC comparison were used for further analysis of the data and for calculation of the sensitivity and specificity of PELP1 quantification in relation to normal/abnormal semen quality. Data were considered statistically significant at P < 0.05.

RESULTS
PELP1 mRNA and protein validation
PELP1 amplification was confirmed in all analyzed samples using specific primers and TaqMan® probes (Roche, assay N° 05046157001 for HPRT, and probe #62 Roche cat. N°: 04688619001 for PELP1). The reaction product specificity was evaluated by electrophoretic separation in agarose gel, sequencing, and alignment analysis. Based on comparison with the molecular size marker Nova l00 (Novazym, Poznan Poland), bands were observed at a size corresponding to the PELP1 mRNA fragment, in length of 100 bp (Figure 2). The consensus sequence of the PCR product was confirmed by sequencing analysis and compared to the mRNA of human PELP1, transcript variant 1 (GenBank N°: NM_014389.2).

PELP1 localization was observed in ovarian cancer tissue samples originating from patients with disturbances in sperm quality. In cells with normal morphology, strong immunostaining was observed in the midpieces. Likewise, in cells with disturbed morphology (of head, midpiece, and/or tail), PELP1 protein was mostly presented within midpieces. Nuclear PELP1 localization was observed in ovarian cancer tissue samples (positive controls) (Figure 4).

FACS analysis quantified sperm with PELP1 expression. For each sample, 10,000 cells were analyzed. The intensity of fluorescence of PELP1-positive sperm was lower in normozoospermic semen (42.78% ± 6.01% vs 61.05% ± 21.70% respectively; P = 0.014; Figure 5). In all analyzed parameters, with the exception of viability and total motility, there were differences between mean fluorescence intensity (P ≤ 0.001). The mean expression level was higher in samples with abnormal semen parameters. In the analysis presented in Supplementary Table 2, the parameters described in each row were taken under consideration as the major subgroup determinant (P < 0.01). A negative correlation was found between all sperm parameters and PELP1 expression. The correlation coefficients varied from −0.41 to −0.59 (P < 0.01; Supplementary Table 3 and Figure 6). ROC curve analyses for the “normal/abnormal” semen categories revealed areas under the curve (AUC) for PELP1 quantification (0.781; P = 0.0001). The cutoff value of 42.15 made it possible to predict the abnormality in semen quality with a sensitivity of 88% and specificity of 65%.

DISCUSSION
Our analysis of mRNA and protein expression revealed, for the first time, the presence of PELP1 in human spermatozoa using four precise,

Western blot analysis confirmed the presence of the PELP1 protein in sperm cells. Immunoreactive bands were observed at approximately 170 kDa, corresponding to the molecular weight of human PELP1. A weak signal was detected in the case of total cellular proteins isolated from swim-up prepared spermatozoa, while a stronger signal was observed in the positive control samples (proteins isolated from ovarian cancer cell line OVCAR-3). The 37 kDa bands of GAPDH reference protein were strongly immunoreactive in all cases (Figure 3).

Expression pattern analysis
Immunocytochemical staining confirmed the presence of PELP1 protein in human sperm. In cells with normal morphology, strong immunostaining was observed in the midpieces. Likewise, in cells with disturbed morphology (of head, midpiece, and/or tail), PELP1 protein was mostly presented within midpieces. Nuclear PELP1 localization was observed in ovarian cancer tissue samples (positive control) (Figure 4).

FACS analysis quantified sperm with PELP1 expression. For each sample, 10,000 cells were analyzed. The intensity of fluorescence of PELP1-positive sperm was lower in normozoospermic semen (42.78% ± 6.01% vs 61.05% ± 21.70% respectively; P = 0.014; Figure 5). In all analyzed parameters, with the exception of viability and total motility, there were differences between mean fluorescence intensity (P ≤ 0.001). The mean expression level was higher in samples with abnormal semen parameters. In the analysis presented in Supplementary Table 2, the parameters described in each row were taken under consideration as the major subgroup determinant (P < 0.01). A negative correlation was found between all sperm parameters and PELP1 expression. The correlation coefficients varied from −0.41 to −0.59 (P < 0.01; Supplementary Table 3 and Figure 6). ROC curve analyses for the “normal/abnormal” semen categories revealed areas under the curve (AUC) for PELP1 quantification (0.781; P = 0.0001). The cutoff value of 42.15 made it possible to predict the abnormality in semen quality with a sensitivity of 88% and specificity of 65%.

DISCUSSION
Our analysis of mRNA and protein expression revealed, for the first time, the presence of PELP1 in human spermatozoa using four precise,
independent techniques. The qualitative presence of transcripts and protein was established by reverse transcription-polymerase chain reaction (RT-PCR) and western blot protocols, respectively. The cellular localization of PELP1 was investigated immunocytochemically. Quantitative analysis of PELP1-positive cells was performed using flow cytometry (FACScalibur®; Becton Dickinson Biosciences).

Until this point, no studies have indicated the presence of PELP1 in spermatozoa. We suspect that PELP1 contributes to the biology of sperm cells. This protein is involved in both genomic and nongenomic pathways of estrogen signal transduction in somatic cells.\textsuperscript{35–39}

Besides the presence of RNA, the protein inheritance in mature sperm was confirmed by the western blot analysis. Detection of PELP1 protein can be supported by the presence of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) in the midpiece region of spermatozoa.\textsuperscript{40} PI3K is involved in estrogen action, transduced via ESRs. PI3K can influence the regulation of calcium channels through phosphatidylinositol (3,4,5)-trisphosphate and diacylglycerol. Those findings are interesting especially in the context of increased Ca\textsuperscript{2+} concentrations observed in the sperm in a quick/nongenomic response to estrogens.\textsuperscript{41} The PELP1 expression pattern observed using Axiosphot light microscopy indicated its localization in the same region as PI3K in sperm with normal and abnormal parameters (Figure 4). Considering studies reporting on different cellular localization of PELP1 (cytoplasmic vs nuclear), its function is compartment dependent.\textsuperscript{42}

Moreover, it has been reported that one ESR isoform can interact with a G-protein-coupled estrogen receptor located in the midpiece.\textsuperscript{43,44} Due to PELP1 interaction with ESR, such localization seems to be justified. The presence of ESRs and PELP1 in the same cellular region could be related to a potential role of estrogens in energy production for motility, capacitation reaction, and sperm fertilizing ability.

In this study, we did not observe significant differences in the PELP1 expression pattern regarding total motility and viability parameters. Surprisingly, in the case of other analyzed parameters, the percentage of PELP1-positive spermatozoa was higher in sperm samples with abnormal parameters. A negative correlation was observed between decreasing PELP1 expression and increasing sperm quality. This may be due to an excess of residual cytoplasm in disturbed sperm morphology or protein redistribution. Moreover, PELP1 was reported to induce nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, which is related to inflammatory signals that modulate macrophage activation.\textsuperscript{45} Taking all of these into account, this could lead to decrease of sperm parameters.

For the first time, our study demonstrates the presence of PELP1 in spermatozoa and its increased expression in sperm with abnormal parameters.

**CONCLUSIONS**

This study demonstrates the presence of mRNA, protein, and cellular localization of PELP1 in ejaculated spermatozoa. Flow cytometry analysis showed that the percentage of sperm cells stained with PELP1 antibody is negatively correlated with increasing sperm quality. Thus, it might be a marker of impaired semen quality. To evaluate the exact role of PELP1 in male germ cell development, as well as in mature sperm physiology and pathology, further studies need to be conducted.

**AUTHOR CONTRIBUTIONS**

JL was responsible for conception and design of the study, acquisition, analysis and interpretation of data, and drafting the article. MA, MK, and PJ participated in the study design, its coordination, as well as in analysis and interpretation of data, and revising the article critically.
for important intellectual content. IS, MA, MS, MJ, and PU carried out study analyses, including protein immunolocalization analyses, PCR, flow cytometry, and are also responsible for revising the article critically for important intellectual content. All authors read and approved the final version of the manuscript and agreed with the order of presentation of the authors.

COMPETING INTERESTS
All authors declared no competing interests.

ACKNOWLEDGMENTS
This work was supported by the National Science Centre Poland grant number: UMO-2016/23/D/NZ5/02604). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Supplementary information is linked to the online version of the paper on the Asian Journal of Andrology website.

REFERENCES
1. Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Hum Reprod Update 2015; 21: 411–26.
2. Bieniek IM, Lo KC. Recent advances in understanding and managing male infertility. F1000Res 2016; 5: 2756.
3. Bonache S, Mata A, Ramos MD, Bassas L, Larría S. Sperm gene expression profile is related to pregnancy rate after insemination and is predictive of low fecundity in normozoospermic men. Hum Reprod 2012; 27: 1556–67.
4. Gnanzo M, Muñoz-Hoyos I, Urizar-Arenaza I, Larrañeta Z, Quintana F, et al. Angiotensin II type 2 receptor is expressed in human sperm cells and is involved in sperm motility. Fertil Steril 2016; 105: 608–16.
5. Carreau S, Bouraima-Lelong H, Delalande C. Estrogens: new players in spermatogenesis. Reprod Biol 2011; 11: 174–93.
6. Carreau S, Wolczynski S, Galeraud-Denis I. Aromatase, oestrogens and human male reproduction. Philos Trans R Soc Lond B Biol Sci 2010; 365: 1571–9.
7. Dostalova P, Zatecka E, Dvorakova-Hortova K. Of oestrogens and sperm: a review of the roles of oestrogens and oestrogen receptors in male reproduction. Int J Mol Sci 2017; 18: 904.
8. Carreau S, Bois C, Zanatta L, Silva FR, Bouraima-Lelong H, et al. Estrogen signaling in testicular cells. Life Sci 2011; 89: 584–7.
9. Walker WH. Testosterone signaling and the regulation of spermatogenesis. Spermatogenesis 2011; 1: 116–20.
10. Chimento A, Sirianni R, Casaburi I, Pezzi V. Role of estrogen receptors and g protein-coupled estrogen receptor in regulation of hypothalamus-pituitary-testis axis and spermatogenesis. Front Endocrinol (Lausanne) 2014; 5: 1.
11. Akingbemi BT. Estrogen regulation of testicular function. Reprod Biol Endocrinol 2005; 3: 51.
12. Carreau S, Hess RA. Oestrogens and spermatogenesis. Philos Trans R Soc Lond B Biol Sci 2010; 365: 1517–35.
13. Carreau S, Silandre D, Bourguiba S, Hamed K, Said L, et al. Estrogens and male reproduction: a new concept. Braz J Med Biol Res 2007; 40: 761–8.
14. Guido C, Perrotta L, Panza S, Middea E, Aversa P, et al. Human sperm physiology.
estrogen receptor alpha (ER\(\alpha\)) and estrogen receptor beta (ER\(\beta\)) influence sperm metabolism and may be involved in the pathophysiology of varicocele-associated male infertility. J Cell Physiol 2011; 226: 3403–12.

Sebkova N, Cerna M, Ded L, Pol Š, Skibinska I, Jendraszak M, Borysiak K, Jendrzejczak P. Influence of 17\(\beta\)-estradiol, genistein and bisphenol A on spermatozoa mitochondrial function. Asian J Androl 2011; 13: 19–25.

Ded L, Dostalova P, Dvorakova-Hortova K, Peknicova J, Borysiak K, Jendrzejczak P. Effect of estrogens on boar sperm capacitation and acrosome reaction. Reprod Biol Endocrinol 2010; 8: 87.

Mohamed ES, Park YJ, Song WH, Shin DH, You YA, Metoděj L, Dostalova P, Dorosh A, Dvorakova-Hortova K, Peknicova J. Effect of estrogens on capacitation and acrosome reaction in porcine sperm. Endocrinol Metab 2007; 22: 420–28.

Filannino A, Stout TA, Gadella BM, Sostaric E, Pizzi F, et al. Dose-response effects of estrogenic mycotoxins (zearalenone, alpha- and beta-zearalenol) on motility, hyperactivation and the acrosome reaction of stallion sperm. Mol Hum Reprod 2010; 16: 555–61.

Filannino A, Stout TA, Gadella BM, Sostaric E, Pizzi F, et al. Synthetic estrogen -estradiol modifies sperm hyperactivation and the acrosome reaction of stallion sperm. Mol Hum Reprod 2011; 17: 179–86.

Gur Y, Breitbart H. Mammalian sperm translate nuclear-encoded proteins by mitochondrial-type ribosomes. Genes Dev 2006; 20: 411–6.

World Health Organization. WHO laboratory manual for the examination and processing of human semen. 5th ed. Geneva: World Health Organization; 2010. p: 1–286.

Chomczyński P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156–9.

Skibińska I, Tomaszewski M, Andrusiewicz M, Urbaniaik P, Czarnecka-Klos R, et al. Expression of estrogen receptor coactivator Proliner–glutamic acid and leucine-rich protein 1 within parapinal muscles in adolescents with idiopathic scoliosis. PLoS One 2016; 11: e0152286.

Marchiani S, Tamburrino L, Ricci B, Nosí D, Cambi M, et al. SUMO1 in human sperm: new targets, role in motility and morphology and relationship with DNA damage. Reproduction 2014; 148: 453–67.

Marchiani S, Tamburrino L, Giuliano L, Nosí D, Solari V, et al. SUMOylation of human spermatozoa and its relationship with semen quality. Int J Androl 2011; 34: 581–93.

Raz L, Khan MM, Mahesh VB, Vadlamudi RK, Brann DW. Rapid estrogen signaling in the brain. Neurosignals 2008; 16: 140–53.

Brann DW, Zhang GQ, Wang RM, Mahesh VB, Vadlamudi RK. PELP1 – a novel estrogen receptor-interacting protein. Mol Cell Endocrinol 2008; 290: 2–7.

Boonyaratanaokrit V. Scaffolding proteins mediating membrane-initiated extra-nuclear actions of estrogen receptor. Steroids 2011; 76: 877–84.

Wang G, Guo Y, Zhou T, Shi X, Yu J, et al. In-depth proteomic analysis of the human sperm reveals complex protein compositions. J Proteomics 2013; 79: 114–22.

Baldi E, Luconi M, Marrotta M, Marchiani S, Tamburrino L, et al. Nongenomic activation of spermatozoa by steroid hormones: facts and fictions. Mol Cell Endocrinol 2009; 308: 39–46.

Girard BJ, Daniel AR, Lange CA, Ostrander JH. PELP1: a review of PELP1 and clinical findings. Neurosignals 2014; 21: T79–86.

La Sala G, Farini D, De Felici M. Rapid estrogen signalling in mouse primordial germ cells. Exp Cell Res 2010; 316: 1716–27.

Li X, Li H, Jia L, Li X, Rahman N. Oestrogen action and male fertility: experimental interactions, signaling, and biology. Mol Cell Endocrinol 2014; 382: 642–51.

Li X, Li H, Jia L, Li X, Rahman N. Oestrogen action and male fertility: experimental and clinical findings. Cell Mol Life Sci 2015; 72: 3915–30.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

©The Author(s)(2018)
**Supplementary Table 1: Demographic data and comparison of semen characteristics**

| Parameter                          | Normal semen (n=17) | Abnormal semen (n=26) |
|------------------------------------|---------------------|-----------------------|
| Age (year)                         | 31.9±6.5            | 33.6±6.7              |
| Sperm concentration (x10^6 ml⁻¹)   | 87.6±18.7           | 18.3±21.3             |
| Total sperm number (x10^9)         | 370.1±178.3         | 63.3±66.3             |
| Progressive motility (%)           | 37.1±2.9            | 20.2±10.3             |
| Total motility (%)                 | 72.1±4.9            | 52.2±16.9             |
| Sperm morphology (%)               | 31.0±8.2            | 2.2±0.7               |
| Viability (%)                      | 86.5±3.5            | 70.2±12.6             |

All the data are presented as mean±s.d. s.d.: standard deviation

**Supplementary Table 2: Statistical analysis results of proline-, glutamic acid-, and leucine-rich protein 1 mean fluorescence intensity values and semen parameters**

| Parameter                          | Normal                  | Abnormal                 | P         |
|------------------------------------|-------------------------|--------------------------|-----------|
|                                    | n                       | PELP1 expression (mean±s.d.) | n          | PELP1 expression (mean±s.d.) |         |
| Sperm concentration (x10^6 ml⁻¹)   | 25                      | 44.12±10.31              | 18        | 67.32±23.31                   | 0.0007   |
| Progressive motility (%)           | 22                      | 43.36±10.74              | 21        | 64.79±22.43                   | 0.0005   |
| Total motility (%)                 | 37                      | 51.20±17.18              | 6         | 70.03±31.52                   | 0.2      |
| Total sperm number (x10^9)         | 28                      | 44.90±10.06              | 15        | 70.50±24.33                   | 0.001    |
| Sperm morphology (%)               | 17                      | 42.78±11.77              | 26        | 61.05±21.70                   | 0.001    |
| Viability (%)                      | 40                      | 53.62±20.61              | 3         | 56.68±20.36                   | 0.8      |

n: number of valid cases for parameter described in row; samples which did not meet the criteria for at least one standard WHO parameter were classified as abnormal. *Welch’s t-test; Mann-Whitney U-test. s.d.: standard deviation; PELP1: proline-, glutamic acid-, and leucine-rich protein 1; WHO: World Health Organization

**Supplementary Table 3: Correlation between semen parameters and proline-, glutamic acid-, and leucine-rich protein 1 expression**

| Parameter   | R          | P         |
|-------------|------------|-----------|
| Sperm conc. | −0.59      | <0.0001   |
| Progressive | −0.51      | <0.0005   |
| Total       | −0.57      | 0.0001    |
| Sperm conc. | −0.41      | 0.006     |
| Sperm conc. | −0.56      | <0.0001   |
| Viability   | −0.43      | 0.004     |

*Significance level of P value. R: Spearman's rank correlation coefficient value; PELP1: proline-, glutamic acid-, and leucine-rich protein 1